On the other hand, there are notable advancements of NSCLC targeted therapies in the development and utilisation of EGFR and ALK inhibitors, which are majorly 2nd- and 3rd-generation small-molecule therapeutics, aimed at enhancing clinical outcomes through improved safety profiles and increased effectiveness against common resistance mutations [3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.